Reinfections with SARS-CoV-2 have already been documented in humans, although its real incidence is currently unknown. Besides having a great impact on public health, this phenomenon raises the question of immunity generated by a single infection is sufficient to provide sterilizing/protective immunity to a subsequent SARS-CoV-2 re-exposure. The Golden Syrian hamster is a manageable animal model to explore immunological mechanisms able to counteract COVID-19, as it recapitulates pathological aspects of mild to moderately affected patients. Here, we report that SARS-CoV-2-inoculated hamsters resolve infection in the upper and lower respiratory tracts within seven days upon inoculation with the Cat01 (G614) SARS-CoV-2 isolate. Three weeks after the primary challenge, and despite high titres of neutralizing antibodies, half of the animals were susceptible to reinfection by both identical (Cat01, G614) and variant (WA/1, D614) SARS-CoV-2 isolates. However, upon re-inoculation, only nasal tissues were transiently infected with much lower viral replication than those observed after the first inoculation. These data indicate that a primary SARS-CoV-2 infection is not sufficient to elicit a sterilizing immunity in hamster models but protects against lung disease.
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster.
对金丝雀叙利亚仓鼠预防D614-或G614-SARS-CoV-2分离株再次感染的保护作用
阅读:13
作者:Brustolin Marco, Rodon Jordi, RodrÃguez de la Concepción MarÃa Luisa, Ãvila-Nieto Carlos, Cantero Guillermo, Pérez Mónica, Te Nigeer, Noguera-Julián Marc, Guallar VÃctor, Valencia Alfonso, Roca Núria, Izquierdo-Useros Nuria, Blanco JuliÃ, Clotet Bonaventura, Bensaid Albert, Carrillo Jorge, Vergara-Alert Júlia, Segalés Joaquim
| 期刊: | Emerging Microbes & Infections | 影响因子: | 7.500 |
| 时间: | 2021 | 起止号: | 2021 Dec;10(1):797-809 |
| doi: | 10.1080/22221751.2021.1913974 | 研究方向: | 炎症/感染 |
| 疾病类型: | 新冠 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
